Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery
Tóm tắt
Từ khóa
Tài liệu tham khảo
Qaseem, 2010, The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods, Ann Intern Med, 153, 194, 10.7326/0003-4819-153-3-201008030-00010
La Vecchia, 2015, Thyroid cancer mortality and incidence: a global overview, Int J Cancer, 136, 2187, 10.1002/ijc.29251
Vaccarella, 2016, Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis, N Engl J Med, 375, 614, 10.1056/NEJMp1604412
Mazzaferri, 2001, Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer, J Clin Endocrinol Metab, 86, 1447, 10.1210/jcem.86.4.7407
Van Nostrand, 2009, The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer, Thyroid, 19, 1381, 10.1089/thy.2009.1611
Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, 1674, 10.1056/NEJMoa1109589
Schlumberger, 2012, Tumeurs de la Thyroide Refractaires Network for the Essai Stimulation Ablation Equivalence T. Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, 1663, 10.1056/NEJMoa1108586
Verburg, 2014, Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients, J Clin Endocrinol Metab, 99, 4487, 10.1210/jc.2014-1631
Luster, 2008, European Association of Nuclear M. Guidelines for radioiodine therapy of differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 35, 1941, 10.1007/s00259-008-0883-1
Edge, 2010
Brierley, 2017
Borson-Chazot, 2008, Guidelines for the management of differentiated thyroid carcinomas of vesicular origin, Ann Endocrinol (Paris), 69, 472, 10.1016/j.ando.2008.10.002
Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158
Haugen, 2016, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer, Thyroid, 26, 1, 10.1089/thy.2015.0020
American Thyroid Association Guidelines Taskforce on Thyroid N, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 19, 1167, 10.1089/thy.2009.0110
Chereau, 2014, Does extracapsular extension impact the prognosis of papillary thyroid microcarcinoma?, Ann Surg Oncol, 21, 1659, 10.1245/s10434-013-3447-y
Youngwirth, 2017, Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer, Thyroid, 27, 626, 10.1089/thy.2016.0132
Adam, 2015, Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer, J Clin Oncol, 33, 2370, 10.1200/JCO.2014.59.8391
Randolph, 2012, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension, Thyroid, 22, 1144, 10.1089/thy.2012.0043
Bardet, 2015, Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer, J Clin Endocrinol Metab, 100, 132, 10.1210/jc.2014-1199
Francis, 2015, Management Guidelines for children with thyroid nodules and differentiated thyroid cancer, Thyroid, 25, 716, 10.1089/thy.2014.0460
Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 18, 1674, 10.1056/NEJMoa1109589
Schlumberger, 2012, Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 18, 1663, 10.1056/NEJMoa1108586
Hay, 2002, Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients, World J Surg, 26, 879, 10.1007/s00268-002-6612-1
Lamartina, 2015, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature, J Clin Endocrinol Metab, 100, 1748, 10.1210/jc.2014-3882
Xu, 2017, Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features, Thyroid, 27, 512, 10.1089/thy.2016.0649
Lee, 2014, Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence, World J Surg, 38, 858, 10.1007/s00268-013-2345-6
Lango, 2013, Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression, Thyroid, 23, 1099, 10.1089/thy.2013.0027
Ruel, 2015, Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer, J Clin Endocrinol Metab, 100, 1529, 10.1210/jc.2014-4332
Yin, 2016, Prognostic impact of minimal extrathyroidal extension in papillary thyroid carcinoma, Medicine (Baltimore), 95, e5794, 10.1097/MD.0000000000005794
Tavarelli, 2017, Heterogeneous prognoses for pT3 papillary thyroid carcinomas and impact of delayed risk stratification, Thyroid, 10.1089/thy.2016.0512
Hugo, 2012, Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence, Thyroid, 22, 1007, 10.1089/thy.2012.0183
Higashi, 2011, Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases, J Nucl Med, 52, 683, 10.2967/jnumed.110.081059
Lee, 2010, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis clinical outcomes and prognostic factors, Ann Surg, 251, 114, 10.1097/SLA.0b013e3181b7faf6
Smallridge, 2014, Practice trends in patients with persistent detectable thyroglobulin and negative diagnostic radioiodine whole body scans: a survey of American Thyroid Association members, Thyroid, 24, 1501, 10.1089/thy.2014.0043
Rosario, 2014, Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?, Thyroid, 24, 533, 10.1089/thy.2013.0427
Khorjekar, 2014, Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?, Thyroid, 24, 1394, 10.1089/thy.2013.0713
Kist, 2016, 124I PET/CT to predict the outcome of blind 131I treatment in patients with biochemical recurrence of differentiated thyroid cancer: results of a Multicenter Diagnostic Cohort Study (THYROPET), J Nucl Med, 57, 701, 10.2967/jnumed.115.168138
Urken, 2015, Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative, Head Neck, 37, 605, 10.1002/hed.23615
Piccardo, 2016, Differentiated thyroid cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy, Eur J Nucl Med Mol Imaging
Rosario, 2015, Adjuvant therapy with 131-iodine in patients with elevated serum thyroglobulin after reoperation due to papillary thyroid carcinoma lymph node metastases, Endocrine, 49, 279, 10.1007/s12020-014-0414-8
Hindie, 2003, Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?, Eur J Nucl Med Mol Imaging, 30, 974, 10.1007/s00259-003-1174-5
Hindie, 2007, Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome, Endocr Relat Cancer, 14, 799, 10.1677/ERC-07-0120
Nixon, 2012, The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland, Thyroid, 22, 884, 10.1089/thy.2011.0535
Sabra, 2013, Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases, J Clin Endocrinol Metab, 98, E829, 10.1210/jc.2012-3933
Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838
Jentzen, 2014, Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging, J Nucl Med, 55, 1759, 10.2967/jnumed.114.144089
Klubo-Gwiezdzinska, 2011, Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer, J Clin Endocrinol Metab, 96, 3217, 10.1210/jc.2011-0494
Deandreis, 2016, Comparison of empiric versus whole body/blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer, J Nucl Med
Zanotti-Fregonara, 2010, On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 37, 2264, 10.1007/s00259-010-1608-9
Freudenberg, 2010, Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons, Eur J Nucl Med Mol Imaging, 37, 2267, 10.1007/s00259-010-1565-3
Plyku, 2017, Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in 124I-PET/CT based dosimetry for 131I therapy of metastatic differentiated thyroid cancer, J Nucl Med, 10.2967/jnumed.116.179366
Potzi, 2006, Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients, Clin Endocrinol (Oxf), 65, 519, 10.1111/j.1365-2265.2006.02626.x
Song, 2015, Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors, Eur J Endocrinol, 173, 399, 10.1530/EJE-15-0296
Ilgan, 2004, Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma, Eur J Nucl Med Mol Imaging, 31, 825, 10.1007/s00259-004-1460-x
Bernier, 2001, Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas, J Clin Endocrinol Metab, 86, 1568, 10.1210/jcem.86.4.7390
Qiu, 2011, Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer, J Clin Endocrinol Metab, 96, 3078, 10.1210/jc.2011-0093
Chiu, 1997, Prognosis and treatment of brain metastases in thyroid carcinoma, J Clin Endocrinol Metab, 82, 3637, 10.1210/jcem.82.11.4386
Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8
Wassermann, 2016, Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas, Oncologist, 21, 50, 10.1634/theoncologist.2015-0107
Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9
Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470
Ho, 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288
Rothenberg, 2015, Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib, Clin Cancer Res, 21, 1028, 10.1158/1078-0432.CCR-14-2915
Aide, 2009, Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer, J Clin Endocrinol Metab, 94, 2075, 10.1210/jc.2008-2313
Avram, 2013, Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?, J Clin Endocrinol Metab, 98, 1163, 10.1210/jc.2012-3630
Avram, 2015, Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning, J Clin Endocrinol Metab, 100, 1895, 10.1210/jc.2014-4043
Lazar, 1999, Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes, J Clin Endocrinol Metab, 84, 3228
Bertagna, 2016, 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. It's value confirmed by a bicentric experience, Curr Radiopharm, 10.2174/1874471009666160523145005
Leboulleux, 2012, Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels, Thyroid, 22, 832, 10.1089/thy.2012.0081
Nascimento, 2015, Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer, Thyroid, 25, 437, 10.1089/thy.2014.0320
Robbins, 2006, Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab, 91, 498, 10.1210/jc.2005-1534
Zanotti-Fregonara, 2009, A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma, Eur J Nucl Med Mol Imaging, 36, 169, 10.1007/s00259-008-0963-2
Park, 2009, Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans, Eur J Nucl Med Mol Imaging, 36, 172, 10.1007/s00259-008-0912-0
Spencer, 2014, How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies, Curr Opin Endocrinol Diabetes Obes, 21, 394, 10.1097/MED.0000000000000092
Gorges, 2005, Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy, Eur J Endocrinol, 153, 49, 10.1530/eje.1.01940